Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Liabilities and Shareholders Equity (2016 - 2025)

Moleculin Biotech's Liabilities and Shareholders Equity history spans 10 years, with the latest figure at $22.1 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $22.1 million for Q4 2025, up 30.73% from a year ago — trailing twelve months through Dec 2025 was $85.1 million (down 12.05% YoY), and the annual figure for FY2025 was $22.1 million, up 30.73%.
  • Liabilities and Shareholders Equity for Q4 2025 was $22.1 million at Moleculin Biotech, up from $20.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $99.8 million in Q1 2021 to a low of $16.9 million in Q4 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $43.3 million (2023), against an average of $49.9 million.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 291.74% in 2021, then crashed 55.71% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $84.1 million in 2021, then plummeted by 31.71% to $57.4 million in 2022, then plummeted by 33.45% to $38.2 million in 2023, then crashed by 55.71% to $16.9 million in 2024, then skyrocketed by 30.73% to $22.1 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $22.1 million, $20.4 million, and $21.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.